person · Reporting owner

Dubow Adam

Disclosed activity across 2 companies

Tapewire entity: 15598
SEC CIK: 0001744507

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BRISTOL MYERS SQUIBB COBMY · Entity 1662	SVP,ChiefCompliance&EthicsOff.	July 30, 2021	August 03, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BRISTOL MYERS SQUIBB CO

Report date July 30, 2021 · Filed August 03, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	13,777.152	Reported balance After 2021-07-30 transaction · row 1 1 source row Row 1 · 2021-07-30 · Sale · Disposed 2,466 · Balance 13,777.152 F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.905 to $67.910, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBMS Savings and Investment Program	971.87	Reported balance Holding disclosure · report date 2021-07-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 971.87 F2: Based on a plan statement as of the end of the most recent fiscal quarter.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.905 to $67.910, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

F2: Based on a plan statement as of the end of the most recent fiscal quarter.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Day One Biopharmaceuticals, Inc.

Report date April 23, 2026 · Filed April 23, 2026

Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-04-23 transaction · row 1 1 source row Row 1 · 2026-04-23 · Disposition to issuer · Disposed 72,694 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2032-10-30	Direct	Reported balance After 2026-04-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-23 · Disposition to issuer · Disposed 309,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The option vests as to 100% of the total shares on November 6, 2026, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2033-01-16	Direct	Reported balance After 2026-04-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-23 · Disposition to issuer · Disposed 90,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-01-04	Direct	Reported balance After 2026-04-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-23 · Disposition to issuer · Disposed 90,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F6: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2035-01-14	Direct	Reported balance After 2026-04-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-23 · Disposition to issuer · Disposed 90,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2036-01-29	Direct	Reported balance After 2026-04-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-04-23 · Disposition to issuer · Disposed 105,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F8: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-04-23 · Disposition to issuer · Disposed 8,889 · Balance 0 F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F10: The Restricted Stock Units ("RSUs") vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vests in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11: RSUs do not expire; they either vest or are canceled prior to the vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-04-23 · Disposition to issuer · Disposed 5,250 · Balance 0 F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11: RSUs do not expire; they either vest or are canceled prior to the vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-04-23 · Disposition to issuer · Disposed 25,816 · Balance 0 F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11: RSUs do not expire; they either vest or are canceled prior to the vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-04-23 · Disposition to issuer · Disposed 40,565 · Balance 0 F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11: RSUs do not expire; they either vest or are canceled prior to the vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-04-23 · Disposition to issuer · Disposed 65,625 · Balance 0 F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11: RSUs do not expire; they either vest or are canceled prior to the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

F3: The option vests as to 100% of the total shares on November 6, 2026, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

F5: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F6: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F7: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F8: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F9: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F10: The Restricted Stock Units ("RSUs") vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vests in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F11: RSUs do not expire; they either vest or are canceled prior to the vesting date.

F12: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 23, 2026 Filed Apr 23, 2026 20:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerRestricted Stock Unit (RSU) · Derivative	65,625	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-26-000005 · form4-04232026_080411.xml · derivative · entry 11 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,625 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerRestricted Stock Unit (RSU) · Derivative	40,565	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-26-000005 · form4-04232026_080411.xml · derivative · entry 10 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,565 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerRestricted Stock Unit (RSU) · Derivative	25,816	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-26-000005 · form4-04232026_080411.xml · derivative · entry 9 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,816 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerRestricted Stock Unit (RSU) · Derivative	5,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-26-000005 · form4-04232026_080411.xml · derivative · entry 8 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,250 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F12 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerRestricted Stock Unit (RSU) · Derivative	8,889	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-26-000005 · form4-04232026_080411.xml · derivative · entry 7 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,889 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F10 · derivative.exercise_date: The Restricted Stock Units ("RSUs") vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vests in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	105,000	Not disclosed Strike: $11.16	Not disclosed	Disclosure SEC source: 0001744507-26-000005 · form4-04232026_080411.xml · derivative · entry 6 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2036-01-29 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F8 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	90,000	Not disclosed Strike: $8.99	Not disclosed	Disclosure SEC source: 0001744507-26-000005 · form4-04232026_080411.xml · derivative · entry 5 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2035-01-14 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	90,000	Not disclosed Strike: $8.99	Not disclosed	Disclosure SEC source: 0001744507-26-000005 · form4-04232026_080411.xml · derivative · entry 4 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2034-01-04 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F6 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	90,000	Not disclosed Strike: $8.99	Not disclosed	Disclosure SEC source: 0001744507-26-000005 · form4-04232026_080411.xml · derivative · entry 3 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2033-01-16 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	309,000	Not disclosed Strike: $8.99	Not disclosed	Disclosure SEC source: 0001744507-26-000005 · form4-04232026_080411.xml · derivative · entry 2 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 309,000 shares Expires 2032-10-30 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The option vests as to 100% of the total shares on November 6, 2026, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerCommon Stock	72,694	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-26-000005 · form4-04232026_080411.xml · nonDerivative · entry 1 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. Read SEC document
February 17, 2026 Filed Feb 18, 2026 22:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	6,395	$11.60	$74,187.76	Disclosure SEC source: 0001744507-26-000004 · form4-02182026_100237.xml · nonDerivative · entry 6 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,694 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.195 to $11.8508, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document
February 15, 2026 Filed Feb 18, 2026 22:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	4,375	$0.00	$0.00	Disclosure SEC source: 0001744507-26-000004 · form4-02182026_100237.xml · derivative · entry 11 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,625 Underlying: Common Stock · 4,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
February 15, 2026 Filed Feb 18, 2026 22:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	3,687	$0.00	$0.00	Disclosure SEC source: 0001744507-26-000004 · form4-02182026_100237.xml · derivative · entry 10 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,565 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
February 15, 2026 Filed Feb 18, 2026 22:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	3,688	$0.00	$0.00	Disclosure SEC source: 0001744507-26-000004 · form4-02182026_100237.xml · derivative · entry 9 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,816 Underlying: Common Stock · 3,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
February 15, 2026 Filed Feb 18, 2026 22:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	1,750	$0.00	$0.00	Disclosure SEC source: 0001744507-26-000004 · form4-02182026_100237.xml · derivative · entry 8 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
February 15, 2026 Filed Feb 18, 2026 22:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	2,963	$0.00	$0.00	Disclosure SEC source: 0001744507-26-000004 · form4-02182026_100237.xml · derivative · entry 7 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,889 Underlying: Common Stock · 2,963 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments thereafter on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
February 15, 2026 Filed Feb 18, 2026 22:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	4,375	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-26-000004 · form4-02182026_100237.xml · nonDerivative · entry 5 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 15, 2026 Filed Feb 18, 2026 22:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	3,687	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-26-000004 · form4-02182026_100237.xml · nonDerivative · entry 4 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 15, 2026 Filed Feb 18, 2026 22:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	3,688	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-26-000004 · form4-02182026_100237.xml · nonDerivative · entry 3 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 15, 2026 Filed Feb 18, 2026 22:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	1,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-26-000004 · form4-02182026_100237.xml · nonDerivative · entry 2 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 15, 2026 Filed Feb 18, 2026 22:17 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	2,963	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-26-000004 · form4-02182026_100237.xml · nonDerivative · entry 1 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
January 30, 2026 Filed Jan 30, 2026 22:15 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantRestricted Stock Units · Derivative	70,000	$0.00	$0.00	Disclosure SEC source: 0001744507-26-000002 · form4-01302026_100154.xml · derivative · entry 2 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
January 30, 2026 Filed Jan 30, 2026 22:15 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	105,000	$0.00 Strike: $11.16	$0.00	Disclosure SEC source: 0001744507-26-000002 · form4-01302026_100154.xml · derivative · entry 1 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2036-01-29 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 17, 2025 Filed Nov 19, 2025 00:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	4,319	$8.91	$38,502.59	Disclosure SEC source: 0001744507-25-000006 · form4-11192025_121106.xml · nonDerivative · entry 5 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,626 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $8.545 to $9.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document
November 15, 2025 Filed Nov 19, 2025 00:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	3,687	$0.00	$0.00	Disclosure SEC source: 0001744507-25-000006 · form4-11192025_121106.xml · derivative · entry 9 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,252 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
November 15, 2025 Filed Nov 19, 2025 00:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	3,687	$0.00	$0.00	Disclosure SEC source: 0001744507-25-000006 · form4-11192025_121106.xml · derivative · entry 8 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,504 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
November 15, 2025 Filed Nov 19, 2025 00:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	1,750	$0.00	$0.00	Disclosure SEC source: 0001744507-25-000006 · form4-11192025_121106.xml · derivative · entry 7 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
November 15, 2025 Filed Nov 19, 2025 00:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	2,963	$0.00	$0.00	Disclosure SEC source: 0001744507-25-000006 · form4-11192025_121106.xml · derivative · entry 6 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,852 Underlying: Common Stock · 2,963 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments thereafter on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
November 15, 2025 Filed Nov 19, 2025 00:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	3,687	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-25-000006 · form4-11192025_121106.xml · nonDerivative · entry 4 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
November 15, 2025 Filed Nov 19, 2025 00:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	3,687	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-25-000006 · form4-11192025_121106.xml · nonDerivative · entry 3 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
November 15, 2025 Filed Nov 19, 2025 00:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	1,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-25-000006 · form4-11192025_121106.xml · nonDerivative · entry 2 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
November 15, 2025 Filed Nov 19, 2025 00:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	2,963	Not disclosed	Not disclosed	Disclosure SEC source: 0001744507-25-000006 · form4-11192025_121106.xml · nonDerivative · entry 1 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:00 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	90,000	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001744507-25-000004 · form4-11072025_111147.xml · derivative · entry 7 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2035-01-14 F2 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F3 · kind: (Continued from Footnote 2) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:00 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	90,000	$0.00 Strike: $11.87	$0.00	Disclosure SEC source: 0001744507-25-000004 · form4-11072025_111147.xml · derivative · entry 6 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2035-01-14 F2 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F3 · kind: (Continued from Footnote 2) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:00 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	90,000	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001744507-25-000004 · form4-11072025_111147.xml · derivative · entry 5 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-01-04 F2 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F3 · kind: (Continued from Footnote 2) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:00 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	90,000	$0.00 Strike: $14.44	$0.00	Disclosure SEC source: 0001744507-25-000004 · form4-11072025_111147.xml · derivative · entry 4 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2034-01-04 F2 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F3 · kind: (Continued from Footnote 2) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:00 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	90,000	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001744507-25-000004 · form4-11072025_111147.xml · derivative · entry 3 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-01-16 F2 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F3 · kind: (Continued from Footnote 2) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:00 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	90,000	$0.00 Strike: $23.41	$0.00	Disclosure SEC source: 0001744507-25-000004 · form4-11072025_111147.xml · derivative · entry 2 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2033-01-16 F2 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F3 · kind: (Continued from Footnote 2) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:00 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	309,000	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001744507-25-000004 · form4-11072025_111147.xml · derivative · entry 1 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,000 Underlying: Common Stock · 309,000 shares Expires 2032-10-30 F1 · derivative.exercise_date: The option vests as to 100% of the total shares on November 6, 2026, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document
August 18, 2025 Filed Aug 19, 2025 23:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	4,365	$6.77	$29,538.39	Disclosure SEC source: 0001415889-25-022382 · form4-08192025_110859.xml · nonDerivative · entry 5 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,858 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $6.65 to $6.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document
August 15, 2025 Filed Aug 19, 2025 23:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	3,687	$0.00	$0.00	Disclosure SEC source: 0001415889-25-022382 · form4-08192025_110859.xml · derivative · entry 9 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,939 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
August 15, 2025 Filed Aug 19, 2025 23:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	3,687	$0.00	$0.00	Disclosure SEC source: 0001415889-25-022382 · form4-08192025_110859.xml · derivative · entry 8 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,191 Underlying: Common Stock · 3,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
August 15, 2025 Filed Aug 19, 2025 23:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	1,750	$0.00	$0.00	Disclosure SEC source: 0001415889-25-022382 · form4-08192025_110859.xml · derivative · entry 7 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
August 15, 2025 Filed Aug 19, 2025 23:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	2,963	$0.00	$0.00	Disclosure SEC source: 0001415889-25-022382 · form4-08192025_110859.xml · derivative · entry 6 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,815 Underlying: Common Stock · 2,963 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments thereafter on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
August 15, 2025 Filed Aug 19, 2025 23:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	3,687	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-022382 · form4-08192025_110859.xml · nonDerivative · entry 4 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
August 15, 2025 Filed Aug 19, 2025 23:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	3,687	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-022382 · form4-08192025_110859.xml · nonDerivative · entry 3 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
August 15, 2025 Filed Aug 19, 2025 23:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	1,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-022382 · form4-08192025_110859.xml · nonDerivative · entry 2 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
August 15, 2025 Filed Aug 19, 2025 23:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	2,963	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-022382 · form4-08192025_110859.xml · nonDerivative · entry 1 Dubow Adam · CIK 0001744507 · Gen Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
May 16, 2025 Filed May 19, 2025 21:48 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	4,552	$6.26	$28,485.96	Disclosure SEC source: 0001415889-25-013682 · form4-05192025_090500.xml · nonDerivative · entry 5 Dubow Adam · CIK 0001744507 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,136 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $6.19 to $6.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.